Research programme: cannabidiol-based therapeutics - KannaLife Sciences

Drug Profile

Research programme: cannabidiol-based therapeutics - KannaLife Sciences

Alternative Names: Cannabinoid-based antioxidants - KannaLife Sciences; Cannabinoid-based neuroprotectants - KannaLife Sciences; KLS-13019

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KannaLife Sciences
  • Class Analgesics; Anti-inflammatories; Benzene derivatives; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Hepatic encephalopathy; Neuropathic pain

Most Recent Events

  • 22 Sep 2017 KannaLife Sciences has patent protection for cannabidiol-based therapeutics in USA
  • 05 Jul 2017 Preclinical trials in Neuropathic pain in USA (unspecified route) before July 2017
  • 29 Feb 2016 Preclinical trials in Brain injuries in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top